Zydus Lifesciences Limited
ZYDUSLIFE
Classement en actions
#1750
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Prix de l'action
$12.04
Capitalisation boursière
$12.01B
Changement (1 jour)
-2.15%
Changement (1 an)
6.00%
Pays
IN
Échange Zydus Lifesciences Limited (ZYDUSLIFE)
Catégorie
Healthcare
Revenus pour Zydus Lifesciences Limited (ZYDUSLIFE)
Revenus en Jun 2026 TTM : $3.16B
Selon les derniers rapports financiers de Zydus Lifesciences Limited, le chiffre d'affaires actuel de l'entreprise (TTM) est de $3.16B. En 2025, l'entreprise a réalisé un chiffre d'affaires de $2.72B une augmentation par rapport à le chiffre d'affaires de l'année 2024, qui était de $2.34B. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Zydus Lifesciences Limited de 2004 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $3.16B | 16.11% |
| 2025 | $2.72B | 15.92% |
| 2024 | $2.34B | 11.77% |
| 2023 | $2.10B | 5.37% |
| 2022 | $1.99B | 1.17% |
| 2021 | $1.97B | 4.00% |
| 2020 | $1.89B | -0.21% |
| 2019 | $1.90B | 3.69% |
| 2018 | $1.83B | 26.46% |
| 2017 | $1.45B | 1.62% |
| 2016 | $1.42B | 2.63% |
| 2015 | $1.39B | 15.37% |
| 2014 | $1.20B | 3.47% |
| 2013 | $1.16B | 15.71% |
| 2012 | $1.00B | 0.20% |
| 2011 | $1.00B | 22.04% |
| 2010 | $820.89M | 45.59% |
| 2009 | $563.82M | -0.43% |
| 2008 | $566.27M | 37.48% |
| 2007 | $411.90M | 26.93% |
| 2006 | $324.50M | 14.00% |
| 2005 | $284.66M | 3.30% |
| 2004 | $275.56M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 109.54% |
IN
|
